Abstract

Proper disinfection using adequate disinfecting agents will be necessary for infection control strategies against coronavirus disease 2019 (COVID-19). However, limited guidance exists on effective surface disinfectants or best practices for their use against severe acute respiratory coronavirus 2. We outlined a process of fully characterizing over 350 products on the Environmental Protection Agency List N, including pH, method of delivery, indication for equipment sterilization, and purchase availability. We then developed a streamlined set of guidelines to help rapidly evaluate and select suitable disinfectants from List N, including practicality, efficacy, safety, and cost/availability. This resource guides the evaluation of ideal disinfectants amidst practical considerations posed by the COVID-19 pandemic.

Details

Title
Considerations for the Selection and Use of Disinfectants Against SARS-CoV-2 in a Health Care Setting
Author
Tyan, Kevin 1   VIAFID ORCID Logo  ; Levin, Adriane 2 ; Avalos-Pacheco, Alejandra 3 ; Plana, Deborah 4 ; Rand, Eleanor A 5 ; Yang, Helen 6 ; Maliszewski, Laura E 7 ; Chylek, Lily A 8 ; Atta, Lyla 9 ; Tye, Mark A 10 ; Carmack, Mary M 11 ; Oglesby, N Synclaire 12 ; Burgin, Susan 13 ; Yu, Sherry H 14 ; LeBoeuf, Nicole R 15 ; Kemp, Jacqueline M 2 

1  Greater Boston Pandemic Fabrication Team (PanFab) c/o Harvard-MIT Center for Regulatory Science, Harvard Medical School, Boston, Massachusetts, USA; Harvard Medical School, Boston, Massachusetts, USA 
2  Greater Boston Pandemic Fabrication Team (PanFab) c/o Harvard-MIT Center for Regulatory Science, Harvard Medical School, Boston, Massachusetts, USA; Department of Dermatology, Brigham and Women’s Hospital, Boston, Massachusetts, USA 
3  Greater Boston Pandemic Fabrication Team (PanFab) c/o Harvard-MIT Center for Regulatory Science, Harvard Medical School, Boston, Massachusetts, USA; Harvard-MIT Center for Regulatory Science, Harvard Medical School, Boston, Massachusetts, USA; Dana-Farber Cancer Institute, Boston, Massachusetts, USA 
4  Greater Boston Pandemic Fabrication Team (PanFab) c/o Harvard-MIT Center for Regulatory Science, Harvard Medical School, Boston, Massachusetts, USA; Harvard-MIT Division of Health Sciences & Technology, Cambridge, Massachusetts, USA; Harvard Ludwig Cancer Research Center and Department of Systems Biology, Harvard Medical School, Boston, Massachusetts, USA 
5  Greater Boston Pandemic Fabrication Team (PanFab) c/o Harvard-MIT Center for Regulatory Science, Harvard Medical School, Boston, Massachusetts, USA; Harvard University Department of Systems Biology, Cambridge, Massachusetts, USA 
6  Greater Boston Pandemic Fabrication Team (PanFab) c/o Harvard-MIT Center for Regulatory Science, Harvard Medical School, Boston, Massachusetts, USA; Harvard-MIT Center for Regulatory Science, Harvard Medical School, Boston, Massachusetts, USA 
7  Greater Boston Pandemic Fabrication Team (PanFab) c/o Harvard-MIT Center for Regulatory Science, Harvard Medical School, Boston, Massachusetts, USA; Harvard-MIT Center for Regulatory Science, Harvard Medical School, Boston, Massachusetts, USA; Harvard Program in Therapeutic Science, Cambridge, Massachusetts, USA; Laboratory of Systems Pharmacology, Department of Systems Biology, Harvard Medical School, Boston, Massachusetts, USA 
8  Greater Boston Pandemic Fabrication Team (PanFab) c/o Harvard-MIT Center for Regulatory Science, Harvard Medical School, Boston, Massachusetts, USA; Laboratory of Systems Pharmacology, Department of Systems Biology, Harvard Medical School, Boston, Massachusetts, USA 
9  Greater Boston Pandemic Fabrication Team (PanFab) c/o Harvard-MIT Center for Regulatory Science, Harvard Medical School, Boston, Massachusetts, USA; Johns Hopkins University School of Medicine, Baltimore, Maryland, USA 
10  Greater Boston Pandemic Fabrication Team (PanFab) c/o Harvard-MIT Center for Regulatory Science, Harvard Medical School, Boston, Massachusetts, USA; Harvard University Graduate School of Arts and Sciences, Cambridge, Massachusetts, USA; Massachusetts General Hospital Center for Systems Biology, Boston, Massachusetts, USA 
11  Greater Boston Pandemic Fabrication Team (PanFab) c/o Harvard-MIT Center for Regulatory Science, Harvard Medical School, Boston, Massachusetts, USA; Harvard-MIT Center for Regulatory Science, Harvard Medical School, Boston, Massachusetts, USA; Computational Health Informatics Program, Boston Children’s Hospital, Boston, Massachusetts, USA 
12  Greater Boston Pandemic Fabrication Team (PanFab) c/o Harvard-MIT Center for Regulatory Science, Harvard Medical School, Boston, Massachusetts, USA; Harvard Program in Therapeutic Science, Cambridge, Massachusetts, USA 
13  Greater Boston Pandemic Fabrication Team (PanFab) c/o Harvard-MIT Center for Regulatory Science, Harvard Medical School, Boston, Massachusetts, USA; Harvard Medical School, Boston, Massachusetts, USA; Brigham and Women’s Hospital, Boston, Massachusetts, USA 
14  Greater Boston Pandemic Fabrication Team (PanFab) c/o Harvard-MIT Center for Regulatory Science, Harvard Medical School, Boston, Massachusetts, USA; Department of Dermatology, Yale University School of Medicine, New Haven, Connecticut, USA 
15  Greater Boston Pandemic Fabrication Team (PanFab) c/o Harvard-MIT Center for Regulatory Science, Harvard Medical School, Boston, Massachusetts, USA; Department of Dermatology, Brigham and Women’s Hospital, Boston, Massachusetts, USA; Dana-Farber Cancer Institute, Boston, Massachusetts, USA 
Publication year
2020
Publication date
Sep 2020
Publisher
Oxford University Press
e-ISSN
23288957
Source type
Scholarly Journal
Language of publication
English
DOI
https://doi.org/10.1093/ofid/ofaa396
ProQuest document ID
3170949594
Copyright
© The Author(s) 2020. Published by Oxford University Press on behalf of Infectious Diseases Society of America. This work is published under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.